FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080201384> ?p ?o ?g. }

• W3080201384 endingPage "513" @default.
• W3080201384 startingPage "509" @default.
• W3080201384 abstract "Objective: To observe the effects of intravenous methylprednisolone pulse (IVMP) therapy on the recovery of visual acuity and its influencing factors in patients with the relapse of aquaporin (AQP) 4 antibody positive neuromyelitis optica related optic neuritis (NMO-ON). Methods: Retrospective case series. Forty-eight eyes of 35 patients diagnosed as NMO-ON in the Neuro-ophthalmology Clinic of Beijing Tongren Hospital from September 2012 to April 2018 were included in this research. All patients were AQP4 antibody seropositive, and had clinical manifestations of acute optic neuritis, with a history of optic neuritis treated with glucocorticoids effectively. They received the treatment of IVMP 500 mg/d or 1 000 mg/d for 3 to 5 days. The post-treatment and pre-treatment visual acuities were compared. Improving four lines or more was considered as markedly effective, improving two or three lines as effective, and improving one line or no change or a decline as no effect. The impacts of age, visual acuity at onset, relapse rate and dosage on the acute exacerbation of NMO-ON were analyzed. Mann-Whitney U test and Kruskal-Wallis test were used for statistical analysis. Results: Among the 35 patients, there were 2 males and 33 females, aged from 15 to 73 years (median, 36 years). In the 48 eyes of recurrence, the treatment was effective 41.7% (20/48), effective 20.8% (10/48), and ineffective 37.5% (18/48). The IVMP therapy was effective in 25 of 34 eyes with one recurrence and 5 of 14 eyes with two or more recurrences, and the difference was statistically significant (Z=2.315, P=0.021). The efficacy in 13 eyes with preoperative visual acuity not lower than 0.05 (10/13) was better than 35 eyes with preoperative visual acuity lower than 0.05 (20/35), and the difference was statistically significant (Z=1.994, P=0.046). Different ages and doses (1 000 mg/d and 500 mg/d) made no significant difference in the efficacy (P=0.273,0.105). Conclusions: The IVMP therapy is effective for the NMO-ON relapse in patients who were AQP4 antibody seropositive. The effect of IVMP treatment at doses of 500 mg/d and 1 000 mg/d is similar. Furthermore, visual acuity less than 0.05 and more relapses reduce the efficacy in relapsed NMO-ON patients. (Chin J Ophthalmol, 2020, 56: 509-513).目的： 观察静脉注射甲泼尼龙冲击（IVMP）治疗对水通道蛋白4（AQP4）抗体阳性的复发性视神经脊髓炎相关视神经炎（NMO-ON）患者的视力恢复效果及其影响因素。 方法： 回顾性系列病例研究。纳入2012年9月至2018年4月在首都医科大学附属北京同仁医院神经眼科门诊确诊为复发性NMO-ON的35例（48只眼）发病患者。所有患者AQP4抗体检测均为阳性，具有急性视神经炎的临床表现，既往有视神经炎发病史且经糖皮质激素治疗有效，均给予500 mg/d或1 000 mg/d，共3~5 d的IVMP治疗，糖皮质激素序贯减量。治疗后1~2周视力较治疗前提高4行及以上为显效；提高2~3行为有效；变化在1行内或无变化或下降为无效。分析复发次数、治疗前视力、年龄以及糖皮质激素冲击剂量对复发性NMO-ON疗效的影响。采用Mann-Whitney U及Kruskal-Wallis检验进行统计学分析。 结果： 35例患者中男性2例，女性33例；发病年龄15~73岁，中位数36岁。在复发的48只眼中，治疗显效41.7%（20/48），有效20.8%（10/48），无效37.5%（18/48）。复发1次的患眼IVMP治疗总有效率为73.5%（25/34），与复发≥2次的患眼IVMP治疗总有效率（5/14）比较，差异有统计学意义（Z=2.315，P=0.021）。治疗前视力<0.05与≥0.05的患眼IVMP治疗总有效率分别为57.1%（20/35）、10/13，差异有统计学意义（Z=1.994，P=0.046）。不同年龄段间及IVMP剂量500 mg/d与1 000 mg/d间治疗效果比较，差异均无统计学意义（P=0.273，P=0.105）。 结论： IVMP治疗对复发性AQP4抗体阳性NMO-ON患者的视力恢复有效，采用剂量为500 mg/d与1 000 mg/d的IVMP治疗效果相近，IVMP治疗对视力<0.05及复发次数多的患者效果更差。（中华眼科杂志，2020，56：509-513）." @default.
• W3080201384 created "2020-09-01" @default.
• W3080201384 creator A5006671896 @default.
• W3080201384 creator A5018971405 @default.
• W3080201384 creator A5043640246 @default.
• W3080201384 creator A5072074671 @default.
• W3080201384 creator A5075217222 @default.
• W3080201384 creator A5082004323 @default.
• W3080201384 creator A5083668274 @default.
• W3080201384 date "2020-07-11" @default.
• W3080201384 modified "2023-09-26" @default.
• W3080201384 title "[Effects of intravenous methylprednisolone pulse therapy on recurrent optic neuritis associated with aquaporin 4 antibody seropositive neuromyelitis optica]." @default.
• W3080201384 doi "https://doi.org/10.3760/cma.j.cn112142-20190629-00353" @default.
• W3080201384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32842332" @default.
• W3080201384 hasPublicationYear "2020" @default.
• W3080201384 type Work @default.
• W3080201384 sameAs 3080201384 @default.
• W3080201384 citedByCount "1" @default.
• W3080201384 countsByYear W30802013842020 @default.
• W3080201384 crossrefType "journal-article" @default.
• W3080201384 hasAuthorship W3080201384A5006671896 @default.
• W3080201384 hasAuthorship W3080201384A5018971405 @default.
• W3080201384 hasAuthorship W3080201384A5043640246 @default.
• W3080201384 hasAuthorship W3080201384A5072074671 @default.
• W3080201384 hasAuthorship W3080201384A5075217222 @default.
• W3080201384 hasAuthorship W3080201384A5082004323 @default.
• W3080201384 hasAuthorship W3080201384A5083668274 @default.
• W3080201384 hasConcept C118487528 @default.
• W3080201384 hasConcept C126322002 @default.
• W3080201384 hasConcept C141071460 @default.
• W3080201384 hasConcept C159654299 @default.
• W3080201384 hasConcept C187212893 @default.
• W3080201384 hasConcept C203014093 @default.
• W3080201384 hasConcept C2776572573 @default.
• W3080201384 hasConcept C2777014857 @default.
• W3080201384 hasConcept C2778257484 @default.
• W3080201384 hasConcept C2780372218 @default.
• W3080201384 hasConcept C2780640218 @default.
• W3080201384 hasConcept C2781137167 @default.
• W3080201384 hasConcept C71924100 @default.
• W3080201384 hasConceptScore W3080201384C118487528 @default.
• W3080201384 hasConceptScore W3080201384C126322002 @default.
• W3080201384 hasConceptScore W3080201384C141071460 @default.
• W3080201384 hasConceptScore W3080201384C159654299 @default.
• W3080201384 hasConceptScore W3080201384C187212893 @default.
• W3080201384 hasConceptScore W3080201384C203014093 @default.
• W3080201384 hasConceptScore W3080201384C2776572573 @default.
• W3080201384 hasConceptScore W3080201384C2777014857 @default.
• W3080201384 hasConceptScore W3080201384C2778257484 @default.
• W3080201384 hasConceptScore W3080201384C2780372218 @default.
• W3080201384 hasConceptScore W3080201384C2780640218 @default.
• W3080201384 hasConceptScore W3080201384C2781137167 @default.
• W3080201384 hasConceptScore W3080201384C71924100 @default.
• W3080201384 hasIssue "7" @default.
• W3080201384 hasLocation W30802013841 @default.
• W3080201384 hasOpenAccess W3080201384 @default.
• W3080201384 hasPrimaryLocation W30802013841 @default.
• W3080201384 hasRelatedWork W2802476810 @default.
• W3080201384 hasRelatedWork W2883624547 @default.
• W3080201384 hasRelatedWork W2902859681 @default.
• W3080201384 hasRelatedWork W2919487855 @default.
• W3080201384 hasRelatedWork W2945251361 @default.
• W3080201384 hasRelatedWork W2959143016 @default.
• W3080201384 hasRelatedWork W2999945321 @default.
• W3080201384 hasRelatedWork W3193324356 @default.
• W3080201384 hasRelatedWork W3213908047 @default.
• W3080201384 hasRelatedWork W3214013778 @default.
• W3080201384 hasVolume "56" @default.
• W3080201384 isParatext "false" @default.
• W3080201384 isRetracted "false" @default.
• W3080201384 magId "3080201384" @default.
• W3080201384 workType "article" @default.